Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose.

Pharmacogenetics and genomics - 1 Jul 2005

Tai Guoying, Farin Frederico, Rieder Mark J, Dreisbach Albert W, Veenstra David L, Verlinde Christophe L M J, Rettie Allan E

Abstract excerpt

OBJECTIVE: To determine the in-vitro and in-vivo effects of the CYP2C9*11 polymorphism on (S)-warfarin metabolism. METHODS AND RESULTS: The *11 allele that results in mutation of Arg335-->Trp occurred with a frequency of approximately 1% in Caucasian and African-American populations. Four subject...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxylation

Share to In Vitro Techniques

Share to Metabolic Clearance Rate

Share to NADPH-Ferrihemoprotein Reductase

Share to Warfarin

Source

Identifiers

PMID: 15970795
DOI: 10.1097/01.fpc.0000162005.80857.98

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-15970795-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose.PMID 15970795Read ↗

Pharmacogenomics of CYP2C9: Functional and Clinical ConsiderationsSemantic proximity Read ↗

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.Semantic proximity Read ↗

The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin.Semantic proximity Read ↗

Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy.Semantic proximity Read ↗

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.Semantic proximity Read ↗

Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.Semantic proximity Read ↗

The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendationsSemantic proximity Read ↗

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.Semantic proximity Read ↗

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.Semantic proximity Read ↗

Influence of <i>CYP2C9</i> Genotype on Warfarin Dose Among African–Americans and European–AmericansSemantic proximity Read ↗

First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.Semantic proximity Read ↗

Implication of novel CYP2C9*57 (p.Asn204His) variant in coumarin hypersensitivity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.